查看购物车
  • Traditional Chinese
  • English
2021-2031年欧洲人类微生物组市场报告：范围、细分、动态和竞争分析
市场调查报告书
商品编码
1871510

2021-2031年欧洲人类微生物组市场报告：范围、细分、动态和竞争分析

Europe Human Microbiome Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 140 Pages | 订单完成后即时交付

价格

欧洲人类微生物组市场预计将大幅成长，到 2031 年将达到约 9.9966 亿美元，高于 2023 年的 2.0479 亿美元，反映出 2023 年至 2031 年的年复合成长率(CAGR) 为 21.9%。

执行摘要和市场分析

市场主要分为以下几个区域：法国、德国、英国和欧洲其他地区。欧洲在全球人类微生物组市场中扮演着至关重要的角色，预计在2023年至2031年期间将实现强劲成长。这一增长主要得益于针对人类微生物组的研究项目增加以及慢性疾病和紊乱的增加。此外，与人类微生物组相关的各项研究计画的拓展预计也将成为推动欧洲市场成长的主要因素。

市场区隔分析

欧洲人类微生物组市场可以透过几个关键细分市场进行分析：类型、应用和疾病类型。

  • 按类型划分：市场分为产品和软体/服务两类。 2023年，产品类市场占据主导地位，其中产品类又可细分为益生菌及益生元。
  • 按应用领域划分：市场分为治疗、诊断和研究，其中治疗领域在 2023 年占据最大的市场份额。
  • 按疾病类型划分：市场分为肥胖症、糖尿病、自体免疫疾病、癌症、胃肠道 (GIT) 问题等类别，其中 GIT 议题在 2023 年将引领市场。

市场展望

人类微生物组产业的成长和动态受到主要市场参与者投资的显着影响。这些公司大力投资研发，以开发创新益生菌、诊断方法和基于微生物组的疗法。此类投资促进了创新，从而发现了新的菌株、作用机制和治疗应用。临床试验需要大量资金，但对于验证微生物组相关产品的安全性和有效性至关重要。

例如，微生物组图谱技术领域的领导企业 Kanvas Biosciences 在 2023 年 6 月的 Pre-A 轮融资中获得了 1,200 万美元。这笔资金将用于推动其专有平台技术的研发，旨在革新微生物组相关疾病的药物开发。此外，企业间的合作能够加强资源共享、专业知识交流和技术进步，进而加速产品开发。 2023 年 7 月，全球最大的食品饮料公司雀巢与领先的研究中心 APC Microbiome Ireland 建立了重要的合作伙伴关係，双方将致力于研究人类微生物组的各个方面，以开发新的健康促进产品。目前，约有 120 家公司正在投资微生物组分析，并且有许多新创公司正在涌入该领域。主要投资者包括 Flagship Pioneering、Seventure Partners 和 BioGaia，这表明这些投资者的持续投入有望推动市场成长。

国家概况

欧洲人类微生物组市场涵盖英国、德国、法国、义大利、西班牙等国。德国在2023年成为最大的市场，被公认为欧洲乃至全球重要的生物技术研究中心。这主要归功于德国拥有许多大型生物技术公司、先进的研究设施以及雄厚的研发资金。德国持续的研发活动和有利于微生物组疗法开发的政府法规，为该领域带来了巨大的发展机会。例如，2022年，由沃尔夫博士集团（Dr. Wolff Group）生产的Vagisan ProbioFlora被重新分类并获得药品资格，这对整个以微生物组为驱动的製药行业产生了积极影响。

2023年3月，mbiomics GmbH宣布成功完成A轮融资首轮交割，筹集资金1300万欧元（约1500万美元），由MIG Capital领投，High-Tech Grunderfonds、Bayern Kapital及私人投资者参投。 mbiomics利用其专有的高解析度分析平台，设计用于精准治疗的有效微生物群落，并改善临床试验中的患者筛选和监测。

公司简介

人类微生物组市场的主要参与者包括 MaaT Pharma、Ferring Holdings SA、AOBiome Therapeutics Inc、Finch Therapeutics Group Inc、Seres Therapeutics Inc、Merck & Co Inc、Rebiotix, Inc.、Yakult Honsha Co., Ltd.、IFF Nutrition & Biosciences 和 Synthetic Biologics, Inc.。这些公司正在采用各种策略，例如扩张、产品创新以及併购，以增强其产品供应并提高市场份额。

目录

第一章：引言

第二章：执行概要

  • 关键见解

第三章：研究方法

  • 二手研究
  • 初步研究
    • 假设的提出：
    • 宏观经济因素分析：
    • 发展基础数字：
    • 数据三角测量：
    • 国家层面资料：

第四章：欧洲人类微生物组市场概况

  • 概述
  • PEST分析

第五章：欧洲人类微生物组市场－关键市场动态

  • 市场驱动因素
    • 主要市场参与者的重大投资
    • 政府倡议
  • 市场限制
    • 微生物组生产过程中的挑战
  • 市场机会
    • 对研发的大力投入
  • 未来趋势
    • 精准医学的兴起
  • 驾驶员和安全带的影响：

第六章：人类微生物组市场——欧洲分析

  • 2021-2031年欧洲人类微生物组市场收入
  • 欧洲人类微生物组市场预测分析

第七章：欧洲人类微生物组市场分析－按类型划分

  • 产品
  • 软体和服务

第八章：欧洲人类微生物组市场分析－按应用领域划分

  • 疗法
  • 诊断
  • 研究

第九章：欧洲人类微生物组市场分析－依疾病类型划分

  • 肥胖
  • 糖尿病
  • 自体免疫疾病
  • 癌症
  • GIT
  • 其他的

第十章：欧洲人类微生物组市场－国家分析

  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区

第十一章：行业概况

  • 概述
  • 人类微生物组市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第十二章：公司简介

  • MaaT Pharma
  • Ferring Holdings SA
  • AOBiome Therapeutics Inc
  • Finch Therapeutics Group Inc
  • Seres Therapeutics Inc
  • Merck & Co Inc
  • Yakult Honsha Co., Ltd.
  • Rebiotix, Inc.
  • IFF Nutrition & Biosciences
  • Synthetic Biologics, Inc.

第十三章：附录

Product Code: TIPRE00003318

The European human microbiome market is projected to grow significantly, reaching approximately USD 999.66 million by 2031, up from USD 204.79 million in 2023, reflecting a compound annual growth rate (CAGR) of 21.9% from 2023 to 2031.

Executive Summary and Market Analysis

The market is divided into key regions: France, Germany, the UK, and the Rest of Europe. Europe plays a crucial role in the global human microbiome market and is anticipated to experience strong growth during the period from 2023 to 2031. This growth is driven by an increase in research studies focused on the human microbiome and a rise in chronic diseases and disorders. Additionally, the expansion of various research initiatives related to human microbiomes is expected to be a primary factor propelling market growth in Europe.

Market Segmentation Analysis

The Europe human microbiome market can be analyzed through several key segments: type, application, and disease type.

  • By Type: The market is categorized into products and software/services. In 2023, the product segment dominated the market, which is further divided into probiotics and prebiotics.
  • By Application: The market is segmented into therapeutics, diagnostics, and research, with therapeutics holding the largest market share in 2023.
  • By Disease Type: The market is classified into categories such as obesity, diabetes, autoimmune disorders, cancer, gastrointestinal (GIT) issues, and others, with GIT issues leading the market in 2023.

Market Outlook

The growth and dynamics of the human microbiome industry are significantly influenced by investments from major market players. These companies are heavily investing in research and development to create innovative probiotics, diagnostics, and microbiome-based treatments. Such investments foster innovation, leading to the discovery of new strains, mechanisms of action, and therapeutic applications. Clinical trials, which require substantial funding, are essential for validating the safety and efficacy of microbiome-related products.

For instance, Kanvas Biosciences, a leader in microbiome mapping technology, secured USD 12 million in a Pre-Series A funding round in June 2023. This funding will support the advancement of their proprietary platform technology aimed at revolutionizing drug development for microbiome-related diseases. Furthermore, collaborations among companies enhance resource sharing, expertise, and technological advancements, accelerating product development. A notable partnership was formed in July 2023 between Nestle, the largest food and beverage company globally, and APC Microbiome Ireland, a leading research center, focusing on various aspects of the human microbiome to develop new health-enhancing products. Currently, around 120 companies are investing in microbiome analysis, with numerous startups entering the sector. Key investors include Flagship Pioneering, Seventure Partners, and BioGaia, indicating that increased investment from these players is likely to drive market growth.

Country Insights

The European human microbiome market includes countries such as the UK, Germany, France, Italy, Spain, and others. Germany emerged as the largest market in 2023, recognized as a significant hub for biotechnological research in Europe and globally. This is attributed to the presence of major biotechnology firms, advanced research facilities, and substantial funding for research and development. The ongoing R&D activities and favorable government regulations for microbiome therapeutics development in Germany present lucrative opportunities. For example, in 2022, Vagisan ProbioFlora, produced by Dr. Wolff Group, was reclassified and received medicinal product status, positively impacting the broader microbiome-driven pharmaceutical industry.

In March 2023, mbiomics GmbH announced a successful first closing of its Series A financing round, raising EUR 13 million (approximately USD 15 million), led by MIG Capital with participation from High-Tech Grunderfonds, Bayern Kapital, and private investors. Mbiomics utilizes its proprietary high-resolution profiling platform to design effective microbial consortia for precision therapies and improve patient selection and monitoring in clinical trials.

Company Profiles

Key players in the human microbiome market include MaaT Pharma, Ferring Holdings SA, AOBiome Therapeutics Inc, Finch Therapeutics Group Inc, Seres Therapeutics Inc, Merck & Co Inc, Rebiotix, Inc., Yakult Honsha Co., Ltd., IFF Nutrition & Biosciences, and Synthetic Biologics, Inc. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their product offerings and increase market share.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. Europe Human Microbiome Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Europe Human Microbiome Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Significant Investments by Key Market Players
    • 5.1.2 Government Initiatives
  • 5.2 Market Restraints
    • 5.2.1 Challenges During Production of Microbiome
  • 5.3 Market Opportunities
    • 5.3.1 Robust Investment in Research and Development
  • 5.4 Future Trends
    • 5.4.1 Emergence of Precision Medicine
  • 5.5 Impact of Drivers and Restraints:

6. Human Microbiome Market - Europe Analysis

  • 6.1 Europe Human Microbiome Market Revenue (US$ Million), 2021-2031
  • 6.2 Europe Human Microbiome Market Forecast Analysis

7. Europe Human Microbiome Market Analysis - by Type

  • 7.1 Product
    • 7.1.1 Overview
    • 7.1.2 Product: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Software and Services
    • 7.2.1 Overview
    • 7.2.2 Software and Services: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Human Microbiome Market Analysis - by Application

  • 8.1 Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Therapeutics: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Diagnostics
    • 8.2.1 Overview
    • 8.2.2 Diagnostics: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.3 Research
    • 8.3.1 Overview
    • 8.3.2 Research: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Human Microbiome Market Analysis - by Disease Type

  • 9.1 Obesity
    • 9.1.1 Overview
    • 9.1.2 Obesity: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 Diabetes
    • 9.2.1 Overview
    • 9.2.2 Diabetes: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.3 Autoimmune Disorder
    • 9.3.1 Overview
    • 9.3.2 Autoimmune Disorder: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.4 Cancer
    • 9.4.1 Overview
    • 9.4.2 Cancer: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.5 GIT
    • 9.5.1 Overview
    • 9.5.2 GIT: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.6 Others
    • 9.6.1 Overview
    • 9.6.2 Others: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Europe Human Microbiome Market - Country Analysis

  • 10.1 Europe
    • 10.1.1 Europe Human Microbiome Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Europe Human Microbiome Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 United Kingdom: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.2.1 United Kingdom: Europe Human Microbiome Market Share - by Type
        • 10.1.1.2.2 United Kingdom: Europe Human Microbiome Market Share - by Product
        • 10.1.1.2.3 United Kingdom: Europe Human Microbiome Market Share - by Application
        • 10.1.1.2.4 United Kingdom: Europe Human Microbiome Market Share - by Disease Type
      • 10.1.1.3 Germany: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.3.1 Germany: Europe Human Microbiome Market Share - by Type
        • 10.1.1.3.2 Germany: Europe Human Microbiome Market Share - by Product
        • 10.1.1.3.3 Germany: Europe Human Microbiome Market Share - by Application
        • 10.1.1.3.4 Germany: Europe Human Microbiome Market Share - by Disease Type
      • 10.1.1.4 France: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.4.1 France: Europe Human Microbiome Market Share - by Type
        • 10.1.1.4.2 France: Europe Human Microbiome Market Share - by Product
        • 10.1.1.4.3 France: Europe Human Microbiome Market Share - by Application
        • 10.1.1.4.4 France: Europe Human Microbiome Market Share - by Disease Type
      • 10.1.1.5 Italy: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.5.1 Italy: Europe Human Microbiome Market Share - by Type
        • 10.1.1.5.2 Italy: Europe Human Microbiome Market Share - by Product
        • 10.1.1.5.3 Italy: Europe Human Microbiome Market Share - by Application
        • 10.1.1.5.4 Italy: Europe Human Microbiome Market Share - by Disease Type
      • 10.1.1.6 Spain: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.6.1 Spain: Europe Human Microbiome Market Share - by Type
        • 10.1.1.6.2 Spain: Europe Human Microbiome Market Share - by Product
        • 10.1.1.6.3 Spain: Europe Human Microbiome Market Share - by Application
        • 10.1.1.6.4 Spain: Europe Human Microbiome Market Share - by Disease Type
      • 10.1.1.7 Rest of Europe: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.7.1 Rest of Europe: Europe Human Microbiome Market Share - by Type
        • 10.1.1.7.2 Rest of Europe: Europe Human Microbiome Market Share - by Product
        • 10.1.1.7.3 Rest of Europe: Europe Human Microbiome Market Share - by Application
        • 10.1.1.7.4 Rest of Europe: Europe Human Microbiome Market Share - by Disease Type

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Human Microbiome Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 MaaT Pharma
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Ferring Holdings SA
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 AOBiome Therapeutics Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Finch Therapeutics Group Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Financial Overview
    • 12.4.4 SWOT Analysis
    • 12.4.5 Key Developments
  • 12.5 Seres Therapeutics Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Merck & Co Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Yakult Honsha Co., Ltd.
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Rebiotix, Inc.
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 IFF Nutrition & Biosciences
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Synthetic Biologics, Inc.
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 List of Abbreviations

List Of Tables

  • Table 1. Europe Human Microbiome Market Segmentation
  • Table 2. Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 3. Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Type
  • Table 4. Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Application
  • Table 5. Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Disease Type
  • Table 6. Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 7. United Kingdom: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
  • Table 8. United Kingdom: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 9. United Kingdom: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 10. United Kingdom: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
  • Table 11. Germany: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
  • Table 12. Germany: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 13. Germany: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 14. Germany: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
  • Table 15. France: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
  • Table 16. France: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 17. France: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 18. France: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
  • Table 19. Italy: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
  • Table 20. Italy: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 21. Italy: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 22. Italy: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
  • Table 23. ADULT OBESITY, 2030
  • Table 24. CHILD OBESITY, 2030
  • Table 25. Spain: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
  • Table 26. Spain: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 27. Spain: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 28. Spain: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
  • Table 29. Rest of Europe: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
  • Table 30. Rest of Europe: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 31. Rest of Europe: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 32. Rest of Europe: Europe Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
  • Table 33. Recent Organic Growth Strategies in the Human Microbiome Market
  • Table 34. Recent Inorganic Growth Strategies in the Human Microbiome Market
  • Table 35. List of Abbreviations

List Of Figures

  • Figure 1. Europe Human Microbiome Market Segmentation - Country
  • Figure 2. PEST Analysis
  • Figure 3. Europe Human Microbiome Market - Key Market Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. Europe Human Microbiome Market Revenue (US$ Million), 2021-2031
  • Figure 6. Europe Human Microbiome Market Share (%) - by Type (2023 and 2031)
  • Figure 7. Product: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Software and Services: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Europe Human Microbiome Market Share (%) - by Application (2023 and 2031)
  • Figure 10. Therapeutics: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Diagnostics: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 12. Research: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Europe Human Microbiome Market Share (%) - by Disease Type (2023 and 2031)
  • Figure 14. Obesity: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Diabetes: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Autoimmune Disorder: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 17. Cancer: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. GIT: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Others: Europe Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Europe Human Microbiome Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 21. United Kingdom: Europe Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 22. Germany: Europe Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 23. France: Europe Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 24. Italy: Europe Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 25. Spain: Europe Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 26. Rest of Europe: Europe Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 27. Growth Strategies in the Human Microbiome Market